Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (21-30 of 263) with videos related to

Pageof 27
Sort By:
Leukemia & Lymphoma|September 13, 2006
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistanceRazelle Kurzrock, Moshe Talpaz, Lan Li, et al.
Biochemical and Biophysical Research Communications|March 15, 2006
The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activationTara C Polek, Moshe Talpaz, Taly Spivak-Kroizman
British Journal of Haematology|February 14, 2002
Cellular signalling pathways: new targets in leukaemia therapyFarhad Ravandi, Moshe Talpaz, Hagop Kantarjian, et al.
Cancer|January 26, 2018
Dasatinib dose management for the treatment of chronic myeloid leukemiaMoshe Talpaz, Giuseppe Saglio, Ehab Atallah, et al.
Internal Medicine (Tokyo, Japan)|May 8, 2002
Current therapy of chronic myelogenous leukemiaGuillermo Garcia-Manero, Moshe Talpaz, Hagop M Kantarjian
Leukemia & Lymphoma|July 28, 2016
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceClaire N Harrison, Moshe Talpaz, Adam J Mead
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?Michael J Mauro, Moshe Talpaz, Jerald P Radich
Blood Reviews|May 2, 2020
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and managementBenjamin Garmezy, Jordan K Schaefer, Jessica Mercer, et al.
Biochemical and Biophysical Research Communications|September 5, 2006
TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosisTara C Polek, Moshe Talpaz, Taly R Spivak-Kroizman
Cancer|April 3, 2015
Meir Wetzler, MDRazelle Kurzrock, Zeev Estrov, Moshe Talpaz, et al.
Pageof 27

Showing results (21-30 of 263) with videos related to

Sort By:
Pageof 27
Leukemia & Lymphoma|September 13, 2006
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistanceRazelle Kurzrock, Moshe Talpaz, Lan Li, et al.
Biochemical and Biophysical Research Communications|March 15, 2006
The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activationTara C Polek, Moshe Talpaz, Taly Spivak-Kroizman
British Journal of Haematology|February 14, 2002
Cellular signalling pathways: new targets in leukaemia therapyFarhad Ravandi, Moshe Talpaz, Hagop Kantarjian, et al.
Cancer|January 26, 2018
Dasatinib dose management for the treatment of chronic myeloid leukemiaMoshe Talpaz, Giuseppe Saglio, Ehab Atallah, et al.
Internal Medicine (Tokyo, Japan)|May 8, 2002
Current therapy of chronic myelogenous leukemiaGuillermo Garcia-Manero, Moshe Talpaz, Hagop M Kantarjian
Leukemia & Lymphoma|July 28, 2016
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceClaire N Harrison, Moshe Talpaz, Adam J Mead
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?Michael J Mauro, Moshe Talpaz, Jerald P Radich
Blood Reviews|May 2, 2020
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and managementBenjamin Garmezy, Jordan K Schaefer, Jessica Mercer, et al.
Biochemical and Biophysical Research Communications|September 5, 2006
TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosisTara C Polek, Moshe Talpaz, Taly R Spivak-Kroizman
Cancer|April 3, 2015
Meir Wetzler, MDRazelle Kurzrock, Zeev Estrov, Moshe Talpaz, et al.
Pageof 27